NASDAQ: MAZE Maze Therapeutics, Inc. 8-K

Maze Therapeutics adds two independent directors, flags late-2026 data readout for MZE829

Filed August 17, 2026 · Period ending August 13, 2026 · ~1 min read

Key Changes

high

Company expects additional MZE829 data in broad AMKD patients in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial initiations for both molecules next year.

Exhibit 99.1 view on EDGAR →
medium

Board appointed Dr. Paula Johnson (Wellesley College President, J&J board member) as Class III director through 2028 and Dr. Sophie Kornowski (former Boston Pharmaceuticals CEO) as Class I director through 2029.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
low

Each new director receives pro-rated $40,000 annual retainer plus committee fees and options to purchase 36,000 shares vesting monthly over 36 months, consistent with standard director compensation policy.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
low

Board rebalanced staggered class composition by moving Dr. Nancy Andrews from Class III to Class II (term now expires 2027) and Hervé Hoppenot from Class II to Class III (term now expires 2028).

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →

Summary

Maze Therapeutics appointed two independent directors with complementary expertise as the company advances toward late-stage development. Dr. Paula Johnson brings over 30 years of clinical and research experience in cardiology and serves on Johnson & Johnson's board; Dr. Sophie Kornowski brings over 35 years of biopharmaceutical leadership including her tenure as CEO of Boston Pharmaceuticals (acquired by GSK).

The appointments add clinical and commercial depth ahead of key pipeline milestones.

The company disclosed its near-term clinical trajectory: additional data from MZE829 (dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease) expected in late 2026 or early 2027, initial data from MZE782 (SLC6A19 inhibitor in Phase 2 for phenylketonuria and chronic kidney disease) in 2027, and additional trial initiations for both molecules next year. These milestones frame the company's path toward late-stage development and pre-commercial planning, the context in which the board added directors with clinical trial execution and commercialization experience.

Section-by-Section Diff

Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation

~1,200 words

Maze Therapeutics appointed two new independent directors and rebalanced board class composition.

2 Added

Added Director appointments medium

Added in current filing · verify on EDGAR →

On August 13, 2026, the Board of Directors (the “Board”) of Maze Therapeutics, Inc. (the “Company”) appointed Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, in each case effective August 13, 2026 (the “Appointment Date”). Dr. Johnson will serve as a Class III director for a term expiring at the Company’s 2028 annual meeting of stockholders, and Dr. Kornowski will serve as a Class I director for a term expiring at the Company’s 2029 annual meeting of stockholders

The Board appointed two new independent directors: Dr. Paula Johnson (President of Wellesley College since 2016, with extensive academic medicine and public health leadership experience) as a Class III director with a term through 2028, and Dr. Sophie Kornowski (former CEO of Boston Pharmaceuticals and Senior Partner at Gurnet Point Capital, with deep biopharmaceutical industry experience) as a Class I director with a term through 2029. Dr. Johnson was assigned to the nominating and corporate governance committee, while Dr. Kornowski was assigned to both the audit and compensation committees.

Show 1 minor / wording change

Added Board class rebalancing low

Added in current filing · verify on EDGAR →

In connection with the foregoing appointments, on August 13, 2026, the Board approved changes to the composition of the classes of the Board so that, as nearly as possible, each class consists of one-third of the total number of directors, as contemplated by the Company’s amended and restated certificate of incorporation. To effect these changes in accordance with the requirements of the Delaware General Corporation Law and the Company’s amended and restated certificate of incorporation, effective August 13, 2026, Nancy C. Andrews, M.D., Ph.D. resigned from her position as a Class III director (with a term expiring at the Company’s 2028 annual meeting of stockholders), subject to and conditioned upon her immediate reappointment as a Class II director, and the Board accepted Dr. Andrews’ resignation and immediately reappointed her as a Class II director with a term expiring at the Company’s 2027 annual meeting of stockholders. Also effective August 13, 2026, Hervé Hoppenot resigned from his position as a Class II director (with a term expiring at the Company’s 2027 annual meeting of stockholders), subject to and conditioned upon his immediate reappointment as a Class III director, and the Board accepted Mr. Hoppenot’s resignation and immediately reappointed him as a Class III director with a term expiring at the Company’s 2028 annual meeting of stockholders.

To maintain balanced staggered board classes after the two new appointments, the Board executed technical director class reassignments. Dr. Nancy Andrews moved from Class III to Class II (term now expires 2027 instead of 2028), and Hervé Hoppenot moved from Class II to Class III (term now expires 2028 instead of 2027). These were immediate resignations and reappointments with no gap in service, purely to rebalance the three classes to approximately equal size as required by the company's charter.

Event · Item 7.01 — Regulation FD Disclosure

~100 words

Maze Therapeutics appointed two new directors to its Board of Directors.

1 Added

Added Board appointments medium

Added in current filing · verify on EDGAR →

On August 13, 2026, the Company issued a press release announcing the appointment of Dr. Johnson and Dr. Kornowski to the Board.

Maze Therapeutics appointed Dr. Johnson and Dr. Kornowski to its Board of Directors on August 13, 2026. The 8-K does not provide biographical details or committee assignments for the new directors.

Event · Exhibit 99.1

~1,500 words View exhibit on EDGAR ↗

2 Added

Added Board appointments medium

Added in current filing · view on EDGAR →

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors.

Maze appointed two new directors to its Board: Paula Johnson, M.D., M.P.H., President of Wellesley College and a J&J board member with over 30 years of clinical and research experience in cardiology, and Sophie Kornowski, Pharm.D., M.B.A., former CEO of Boston Pharmaceuticals (acquired by GSK) with over 35 years of biopharmaceutical leadership experience including roles at Roche and Merck. The appointments add clinical and commercial expertise as the company advances toward late-stage development and pre-commercial planning.

Added Pipeline milestones high

Added in current filing · view on EDGAR →

With key progress made in our development programs, we are looking ahead to several important milestones, including additional data from MZE829 in broad AMKD patients in late 2026 or early 2027, initial data from MZE782 in 2027, and additional trial initiations for both molecules next year

The company disclosed upcoming clinical milestones for its two lead programs: additional data from MZE829 (a dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease) expected in late 2026 or early 2027, initial data from MZE782 (an SLC6A19 inhibitor in Phase 2 for phenylketonuria and chronic kidney disease) expected in 2027, and additional trial initiations for both molecules planned for next year. These milestones frame the company's near-term clinical development trajectory.